Phase IB study of low-dose intraperitoneal recombinant Interleukin-2 in patients with refractory advanced ovarian cancer: Rationale and preliminary report

This publication has 14 references indexed in Scilit:

• Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.
  The Journal of Immunology, 1988
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Intraperitoneal Administration of Interleukin-2 in Patients With Cancer
  Archives of Surgery, 1986
• Intraperitoneal chemotherapy: a review.
  Journal of Clinical Oncology, 1986
• Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia
  Published by Springer Nature ,1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
  The Journal of Immunology, 1985
• Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
  The Journal of Immunology, 1985
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• Induction of suppressor T cells by interleukin 2.
  The Journal of Immunology, 1984